

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYCLLFLUDR

Page 1 of 3

DOCTOR'S ORDERS	Ht	cm	Wt	kg	BSA	m²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form						
Date: To be give	To be given: Cycle #		Cycle #:			
Date of Previous Cycle:						
□ Delay treatment week(s)□ CBC & Diff, Platelets, Creatinine day of treatment	ment					
May proceed with doses as written if within 96 hours ANC <u>greater than or equal to</u> 1.2 x 10 ⁹ /L, Platelets <u>greater than or equal to</u> 100 x 10 ⁹ /L, Creatinine within normal limits						
Note: If the patient has a serum creatinine above normal and for all patients above the age of 60 years, calculated creatinine clearance is required prior to first cycle of fludarabine, but is only required in subsequent cycles if the serum creatinine is above the normal range. Note: If the fludarabine dose was initially reduced, and is well tolerated, the dose may be increased in subsequent cycles regardless of renal function.						
Dose modification for:						
TREATMENT:						
Standard Dose: Oral fludarabine 40 mg/m²/day x BSA = mg PO daily for 5 consecutive days. Round dose to nearest 10 mg. (Note: PO fludarabine and riTUXimab to start on the same day. OR Dose Modification Required: Oral fludarabine 32 mg/m²/day x BSA = mg PO daily for 3 consecutive days. Round dose to nearest 10 mg. (Note: PO fludarabine and riTUXimab to start on the same day)						
OR						
Standard Dose: IV fludarabine 25 mg/m²/day x BSA = mg IV in 100 mL NS over 30 minutes daily for 5 days. (Note: riTUXimab to be given within 72 hours of IV fludarabine) OR Dose Modification Required: IV fludarabine 20 mg/m²/day x BSA = mg IV in 100 mL NS over 30 minutes daily for 3 days. (Note: riTUXimab to be given within 72 hours of IV fludarabine)						
(Continued on Page 2)						
DOCTOR'S SIGNATURE:					SIGNA UC:	ATURE:



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYCLLFLUDR

Page 2 of 3

DOCTOR'S ORDERS					
Date:					
Have Hypersensitivity Reaction Tray and Protocol Available					
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm	_·				
For intravenous riTUXimab infusion: diphenhydrAMINE 50 mg PO prior to riTUXimab IV and then q 4 h if IV infusion exceeds 4 h acetaminophen 650 mg to 975 mg PO prior to riTUXimab IV and then q 4 h if IV infusion exceeds					
For subcutaneous riTUXimab injection: diphenhydrAMINE 50 mg PO prior to riTUXimab subcutaneous acetaminophen 650 mg to 975 mg PO prior to riTUXimab subcutaneous					
☐ Other					
TREATMENT: (continued) riTUXimab IV or subcutaneous may be given before or after chemotherapy, but within 72 hour TREATMENT #1: riTUXimab (first dose) 375 mg/m² x BSA = mg IV in 250 to 500 mL NS within 72 hours after Day 1 of fludarabine.	s after Day 1 of fludarabine				
Pharmacy to select riTUXimab IV brand as per Provincial Systemic Therapy Policy III-190					
Drug Brand (Pharmacist to complete. Please print.) Pharmacist Initial and	d Date				
riTUXimab					
Start at 50 mg/h. After 1 hour, increase rate by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs.					
For the first dose, patients are to be under constant visual observation during all dose increases and for 30 minutes after infusion completed. Vital signs are not required, unless symptomatic.					
DOCTOR'S SIGNATURE:	SIGNATURE:				
	UC:				



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYCLLFLUDR

Page 3 of 3

DOCTOR'S ORDERS	
Date:	
Have Hypersensitivity Reaction Tray and Protocol Avai	lable
TREATMENT: (continued):	
FOR CYCLE 2 AND ALL SUBSEQUENT TREATMENTS:	
☐ Patient tolerated a full dose of IV riTUXimab (no severe reactions requiring early term subcutaneous riTUXimab:	nination) and can proceed to
riTUXimab subcut (RITUXAN SC) 1600 mg (fixed dose in 13.4 mL) subcutaneously Observe for 15 minutes after administration.	into abdomen over 7 minutes.
NB: During treatment with subcutaneous riTUXimab, administer other subcutaneous dru whenever possible.	gs at alternative injection sites
OR	
☐Patient did not tolerate a full dose of IV riTUXimab (experienced severe reactions requirevious treatment and will continue with IV riTUXimab for this cycle:	uiring early termination) in the
riTUXimab 500 mg/m² x BSA = mg	
IV in 250 to 500 mL NS on day 1 of PO fludarabine OR within 72 hours after Day 1 of l	IV fludarabine.
Pharmacy to select riTUXimab IV brand as per Provincial Systemic Therapy Policy III-190)
Drug Brand (Pharmacist to complete. Please print.) Pharmacist Init	ial and Date
riTUXimab	
Infuse 50 mL (or 100 mL of 500 mL bag) of the dose over 30 minutes, then infuse the re 500 mL bag) over 1 hour. (total infusion time = 1 hour 30 min) If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute disc existing symptoms occur, stop infusion and page physician. Constant visual observation	comfort or exacerbation of any
RETURN APPOINTMENT ORDERS	
 □ Return in <u>four</u> weeks for Doctor and Cycle □ For PO fludarabine, book chemo for riTUXimab treatment only. □ For IV fludarabine, book chemo x 5 days OR 3 days (circle one). Match to dose duration above) Note riTUXimab to be booked within 72 hours of IV Fludarabine. □ Last Cycle. Return in week(s). 	
CBC & Diff, Platelets, Creatinine prior to each cycle Other tests: Consults: See general orders sheet for additional requests	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: